A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast|Carcinoma of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|BRCA1 Gene Mutation|BRCA2 Gene Mutation|Ovarian Neoplasms
Interventions: DRUG: niraparib|DRUG: Physician's choice
Sponsor: Tesaro, Inc.
Collaborators: European Organisation for Research and Treatment of Cancer - EORTC|Breast International Group|Myriad Genetic Laboratories, Inc.|US Oncology Research|Sarah Cannon|Facing Our Risk of Cancer Empowered